Article Type
Changed
Thu, 01/26/2023 - 10:58

Key clinical point: Obesity and advanced stage (stage III) at diagnosis of breast cancer (BC) were associated with a higher rate of recurrence and worse prognosis in patients with BC who achieved pathological complete response (pCR) after receiving neoadjuvant chemotherapy (NCT).

Major finding: Obesity vs  no obesity (P = .019) and stage III vs  stage I-II BC at diagnosis (P = .0018) were significantly associated with worse invasive disease-free survival, with obesity demonstrating worse survival outcomes in stage III BC (hazard ratio 4.31; P = .006).

Study details: Findings are from a retrospective real-world analysis including 241 patients with stage I-III BC who had achieved pCR after receiving NCT.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Acevedo F et al. Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy. Sci Rep. 2022;12:21145 (Dec 7). Doi: 10.1038/s41598-022-25043-2

 

Publications
Topics
Sections

Key clinical point: Obesity and advanced stage (stage III) at diagnosis of breast cancer (BC) were associated with a higher rate of recurrence and worse prognosis in patients with BC who achieved pathological complete response (pCR) after receiving neoadjuvant chemotherapy (NCT).

Major finding: Obesity vs  no obesity (P = .019) and stage III vs  stage I-II BC at diagnosis (P = .0018) were significantly associated with worse invasive disease-free survival, with obesity demonstrating worse survival outcomes in stage III BC (hazard ratio 4.31; P = .006).

Study details: Findings are from a retrospective real-world analysis including 241 patients with stage I-III BC who had achieved pCR after receiving NCT.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Acevedo F et al. Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy. Sci Rep. 2022;12:21145 (Dec 7). Doi: 10.1038/s41598-022-25043-2

 

Key clinical point: Obesity and advanced stage (stage III) at diagnosis of breast cancer (BC) were associated with a higher rate of recurrence and worse prognosis in patients with BC who achieved pathological complete response (pCR) after receiving neoadjuvant chemotherapy (NCT).

Major finding: Obesity vs  no obesity (P = .019) and stage III vs  stage I-II BC at diagnosis (P = .0018) were significantly associated with worse invasive disease-free survival, with obesity demonstrating worse survival outcomes in stage III BC (hazard ratio 4.31; P = .006).

Study details: Findings are from a retrospective real-world analysis including 241 patients with stage I-III BC who had achieved pCR after receiving NCT.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Acevedo F et al. Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy. Sci Rep. 2022;12:21145 (Dec 7). Doi: 10.1038/s41598-022-25043-2

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan Commentary: Breast Cancer January 2023
Gate On Date
Tue, 06/22/2021 - 11:15
Un-Gate On Date
Tue, 06/22/2021 - 11:15
Use ProPublica
CFC Schedule Remove Status
Tue, 06/22/2021 - 11:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article